Jonathan M. Edelman

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Lars Lindholm, Hans Ibsen, Björn Dahlöf et al. · The Lancet · 2002 · 1.6K citations

Medicine, Cardiology, Internal Medicine +15

Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial

Kenneth R. Chapman, Jonathan Burdon, Eeva Piitulainen et al. · The Lancet · 2015 · 504 citations

Medicine, Internal Medicine, Pharmacotherapy +9

Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol

Richard B. Devereux, Björn Dahlöf, Eva Gerdts et al. · Circulation · 2004 · 472 citations

Medicine, Cardiology, Pharmacotherapy +17

Effects of Losartan on Cardiovascular Morbidity and Mortality in Patients With Isolated Systolic Hypertension and Left Ventricular Hypertrophy

Sverre E. Kjeldsen, Björn Dahlöf, Richard B. Devereux et al. · JAMA · 2002 · 442 citations

Medicine, Cardiology, Pharmacology +17

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

Lars Lindholm, Hans Ibsen, Knut Borch‐Johnsen et al. · Journal of Hypertension · 2002 · 395 citations

Medicine, Cardiology, Pharmacotherapy +17